Two separate studies presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition—and highlighted in a report published in The ASCO Post—provide preliminary evidence that triplet combinations may have a role in the treatment of acute myeloid leukemia (AML).
